MedTrace Logo

HDDO-1614 Intervention Trial

NCT03234244 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2017-12-11

No results posted yet for this study

Summary

Randomized, Open-label, Single-dose, 3-period, 6-sequence, 3-way crossover Study

Conditions

Interventions

DRUG

Bazedoxifene 20 mg

To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.

DRUG

Cholecalciferol

To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.

DRUG

Bazedoxifene 20mg and Cholecalciferol

For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.

Sponsors & Collaborators

  • Hyundai Pharmaceutical Co., LTD.

    lead INDUSTRY

Principal Investigators

  • Sang-Heon Cho · Inha University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-12
Primary Completion
2017-08-14
Completion
2017-08-14

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03234244 on ClinicalTrials.gov